TABLE 3.
Prospective case‐control study: TEG and coagulation testing values included in statistical analysis with statistical cutoff values and P values.
| Variable | Units | Reference interval | SARDS | Controls | P value |
|---|---|---|---|---|---|
| R time | min | 2‐5 | 4.6 (2.5‐7.1) | 4.7 (3.4‐5.3) | .81 |
| K time | min | 1‐3 | 1.1 (0.8‐1.7) | 1.2 (1‐2) | .49 |
| G | kdynes/s | 4.0‐8.9 | 12.7 (11.2‐25.4) | 10.6 (6.4‐11.8) | .04 |
| Maximum amplitude | mm | 47‐65 | 71.7 (69.1‐83.5) | 68 (56.2‐70.2) | .02 |
| Angle | degrees | 58‐75 | 74.8 (65.9‐79.2) | 72.2 (64.5‐74.9) | .22 |
| Ly30 | % | 0‐8 | 0 (0‐0) | 0 (0‐0.2) | NP |
| AT | % | 65‐145 | .99 | ||
| Fibrinogen | mg/dL | 150‐490 | 463 (391‐680) | 297 (166‐393) | .001 |
| D‐dimer | mg/mL | 0‐575 | 387 (62‐658) | 292 (79‐826) | .85 |
| TAT | μg/L | 6.8‐10.2 | 14.1 (2.4‐154.9) | 8.9 (2.9‐133.5) | .81 |
Note: Adjusted P value cutoffs are presented in Table S1.
Abbreviations: AT, antithrombin; SARDS, sudden acquired retinal degeneration syndrome; TAT, thrombin‐antithrombin; TEG, thromboelastography.